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Bacillus  Calmette-Guerin  (BCG)  vaccination  has been  reported  to protect  neonates  from  non-tuberculous
pathogens,  but no biological  mechanism  to explain  such  effects  is  known.  We  hypothesised  that  BCG
produces  broad-spectrum  anti-microbial  protection  via  a hepcidin-mediated  hypoferraemia,  limiting
iron  availability  for pathogens.
To test  this  we conducted  a  trial  in 120  Gambian  neonates  comparing  iron  status  in the  ﬁrst  5-days
of  life  after  allocation  to: (1)  All  routine  vaccinations  at birth  (BCG/Oral  Polio  Vaccine  (OPV)/Hepatitis  Beywords:
CG
ron
epcidin
eterologous effects
Vaccine  (HBV));  (2)  BCG  delayed  until  after  the study  period  (at day 5);  and (3)  All  routine  vaccinations
delayed  until  after the study  period.
Vaccine  regime  at birth  did  not  signiﬁcantly  impact  on  any  measured  parameter  of  iron  metabolism.
However,  the  ability  to  detect  an  effect  of BCG  on  iron  metabolism  may  have  been  limited  by  short
follow-up  time  and  high  activation  of the  inﬂammatory-iron  axis  in  the  study  population.
ubliseonate ©  2015  The  Authors.  P
. Background
The possibility that BCG vaccination might protect neonates
gainst non-tuberculous infections has been suggested by two
andomised controlled trials [1,2] and numerous epidemiological
tudies [3–7]. However, the theory has failed to gain acceptance,
artly due to the lack of a putative biological mechanism to explain
uch effects. The randomised trials indicated that protection was
trongest within 3 days post-vaccination thus implicating an effect
n innate immunity [2]. We  theorised that BCG might mediate its
eterologous effects by stimulating an iron-withholding response,
s part of an acute phase reaction to vaccination.
Iron is critical for the growth and virulence of the majority of
uman pathogens [8]. The acute phase response produces a rapid
eduction in serum iron limiting its availability for pathogens.
his hypoferraemia is thought to be primarily orchestrated by
L-6 (and possibly other inﬂammatory cytokines) up-regulating
Abbreviations: BCG, Bacillus Calmette-Guerin; EDTA, ethylenediaminetetraace-
ic acid; ELISA, enzyme linked immunosorbant assay; HBV, Hepatitis B Vaccine; IL-6,
nterleukin 6; OPV, oral polio vaccine; TSAT, transferrin saturation.
∗ Corresponding author. Tel.: +44 207 958 8125.
E-mail addresses: sarah.prentice@lshtm.ac.uk (S. Prentice), mwjallow@mrc.gm
M.W.  Jallow), Andrew.prentice@lshtm.ac.uk (A.M. Prentice).
ttp://dx.doi.org/10.1016/j.vaccine.2015.04.087
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
hepcidin in the liver. The iron-regulatory hormone hepcidin acts on
macrophages and enterocytes to internalise the transmembrane
iron-transporter protein ferroportin. This sequesters circulating
iron within macrophages and reduces enteric absorption of dietary
iron.
The kinetics of iron metabolism in the early neonatal period
are poorly described, but it is believed to be a period of high iron
ﬂux. Fetal red cell mass is higher than post-natally [9], with excess
erythrocytes broken down in the ﬁrst few days following birth. Dif-
ﬁculties metabolising the haem component of haemoglobin are
commonly seen in neonates, in the form of jaundice. High iron
loads may  contribute to the enhanced risk of infections that occur
during the neonatal period, exempliﬁed by the 20-fold increased
risk of Escherichia coli sepsis that occurred in Polynesian infants
following provision of iron dextran at birth [10]. Thus, reduc-
tion of serum iron as an innate immune strategy to limit the
growth of pathogens may  be particularly beneﬁcial in the neonatal
period.
The effects of BCG, and other vaccines, on the inﬂammatory-
iron pathway in humans are unknown. Several lines of evidence,
however, suggest that impacts on this pathway do occur: (1) BCG is
a strong inducer of IL-6 [11] and other innate cytokines [12] in-vivo;
(2) live-vaccinations similar to BCG produce strong up-regulation
of hepcidin in ﬁsh [13]; and (3) BCG in guinea-pigs leads to a rapid
bacteriostatic hypoferraemia [14].
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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We  therefore conducted a proof-of-principal controlled trial in
ambian neonates to investigate the impact of BCG, and other vac-
ines received at birth, on iron metabolism in the ﬁrst ﬁve days of
ife.
. Methods
80 healthy Gambian neonates were randomly allocated to
eceive BCG (Danish Strain 1331, Batch 11023B, 0.05 ml  intra-
ermally into the left deltoid) either at birth, or after completion
f study procedures at ﬁve days old. All other routine immuni-
ations (Oral Polio Vaccine (OPV)) and Hepatitis B Vaccine (HBV)
ere given at birth as normal. A data manager not directly involved
n the study, conducted randomisation using Microsoft Access,
pon delivery of an eligible infant. Blocked randomisation using
locks of six with a 1:1 allocation ratio was used. Due to concerns
egarding the potential confounding inﬂuence of OPV and HBV at
irth, a third non-randomised group of 40 infants was subsequently
ecruited and received all vaccinations after completion of study
rocedures at ﬁve days of age. Recruitment ran from May  2013 until
ebruary 2014, with the ﬁrst two, randomised groups, recruited
uring both rainy and dry seasons, and the third non-randomised
roup recruited during the dry season.
All participants had a 2 ml  baseline venous blood sample taken
ithin 24 h of delivery, prior to receipt of any vaccinations, and a
urther 2 ml  venous blood sample taken either 24–48 or 72–96 h
ost-intervention. Blood was collected directly into microtain-
rs (Becton–Dickson: 0.5 ml  collected into EDTA containing tubes,
.5 ml  into lithium–heparin containing tubes) from the dorsum
f the hand. Full blood counts were assessed from EDTA blood
sing the automated Medonic analyser. Lithium–heparinised blood
as centrifuged for 4 min  at 3600 g within 4 h of collection and
he plasma stored at −70 ◦C until analysis. Iron parameters were
easured using the automated Cobas Integra 400 plus (Roche Diag-
ostics). Plasma hepcidin was measured in duplicate, using a 1:20
ilution by competitive ELISA (Bachem-25, USA) with detection
ange 0.02–25 ng/ml. Plasma IL-6 was measured in duplicate using
 1:2 dilution by competitive ELISA (BD OptEIA, Oxford, UK), with
etection range 0.49–250 pg/ml. Samples with readings outside the
inear portion of the curve were re-run at alternative dilutions.
alues below the limit of detection were imputed using limit of
etection/
√
2. Any samples with an intra-assay co-efﬁcient of vari-
nce >15% were re-analysed.
Demographic, birth details and anthropometry were collected
t enrolment. Due to the rural nature of the study site, all births
ere vaginal. Deliveries and follow-up visits were conducted at
he participant’s home.
able 1
opulation characteristics by intervention group.
Group 1 
BCG/OPV/HBV 
n = 40 
Gender (male, %) 51.2 
Gestational age (weeks) 38.2 
Birth  weight (g) 3065 
Length (cm) 50.8 
Head  circumference (cm) 34.4 
Parity  3.2 
Maternal iron supplementation 95.1% 
Timing of pre-intervention blood sample (hours) 6.85 
Admissions to hospital during study perioda 1 
Deaths during study periodb 0 
a All admissions were for presumed neonatal sepsis. All infants received antibiotics and
b One study participant died at home between the ﬁrst and second study visits, cause o
c Categorical variables were compared using the Chi-squared test. Continuous variable3 (2015) 2963–2967
Full informed consent was obtained from mothers antenatally
by a trained midwife. Inclusion criteria were (1) Consenting mother
(2) Residence within the study area. Exclusion criteria were (1)
Infant weighing <2000 g (2) Maternal HIV or TB (3) TB contact in
the home (4) complicated delivery (5) major congenital anomaly
(6) infant unwell as judged by a doctor or a midwife. The Consort
ﬂow diagram for the study can be found as supplementary material.
Clinical investigators and mothers were not blinded to inter-
vention allocation due to lack of feasibility (BCG produces a visible
reaction) and for safety, so that any mothers would be aware
of the vaccination status of the child. Laboratory investigators
were blinded to intervention allocation, with assays conducted by
anonymous study number. Data were analysed using Stata Version
11.0. Categorical variables were compared using the chi-squared
test and continuous variables by one-way ANOVA. Hepcidin and IL-
6 results were not normally distributed and were log-transformed
prior to comparison. Intervention allocation code was not broken
until the data were cleaned and locked.
As this study was  a small proof-of-principal trial, with short
follow-up and no clinical endpoints, no data safety monitoring
board was appointed. Safety data were monitored in real time by
clinical investigators who were not blinded to intervention allo-
cation. There was  no signiﬁcant difference in incidence of serious
adverse events by intervention allocation group (see Table 1).
Ethical approval was  obtained from the joint Gambia Govern-
ment/MRC Unit The Gambia ethics committee (Ref: SCC1325) and
the London School of Hygiene and Tropical Medicine ethics com-
mittee (Ref: 012-045). This trial was conducted according to the
principles of the Declaration of Helsinki.
3. Results
Baseline demographic variables were balanced amongst the
three intervention groups (Table 1), suggesting that adequate ran-
domisation occurred and that the third, non-randomised arm, was
comparable.
As shown in Fig. 1, there was  no signiﬁcant impact of BCG or
other routine immunisations received at birth on any measured
parameters of the inﬂammatory-iron axis at either 24–48 h or
72–96 h post-intervention. No signiﬁcant differences were found
when comparing (1) intervention groups at each blood sampling
point (Table 2), (2) within-infant changes to parameters over time
by intervention group and (3) infants receiving any vaccines at birth
(groups 1 and (2) with vaccination naïve infants (group 3) (data not
shown, all p-values > 0.05). The hepcidin levels in group 3 (recruited
separately in the dry season) showed a trend toward being lower at
all time-points. However this ﬁnding was  not signiﬁcant and was
Group 2 Group 3 p-Valuec
OPV/HBV No vaccines
n = 40 n = 40
48.7 47.5 0.94
38.0 38.1 0.89
3069 3045 0.71
50.5 50.7 0.91
34.1 34.1 0.48
3.6 4.3 0.48
100% 97.5% 0.38
5.92 7.69 0.29
2 1 1.0
0 1 0.33
 improved within 48 h. They were discharged when blood cultures were negative.
f death unknown.
s were compared using one-way ANOVA.
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epresent a true difference.
As previous trials reported more signiﬁcant effects of BCG in
ale infants results were also analysed by gender (Table 2). In gen-
ral no differences in the impact of vaccine timing on parameters by
ender was found. However, IL-6 was signiﬁcantly higher in male
nfants receiving BCG at birth than delayed (p = 0.02), and hepcidin
hich was signiﬁcantly lower in girls who had received all vaccines
elayed (p = 0.004). As these ﬁndings were not reﬂected in changes
o any other parameters of the inﬂammatory-iron axis, they may
eﬂect multiple testing artefacts.) by intervention group and time post-intervention.
4. Discussion
This study found no evidence that BCG or other routine immuni-
sations at birth impact signiﬁcantly on iron metabolism. However,
we may  have failed to identify an inherent ability for vaccinations to
stimulate the inﬂammatory-iron pathway for a number of reasons:
First, BCG is a slowly replicating live-organism and may  take
time to reach a level in the body able to stimulate a systemic
response. The later time-point of 72–96 h post-vaccination may
have been too early to identify any impact of BCG on iron
metabolism.
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Table 2
Comparison of mean iron metabolism pathway parameters by intervention group and time post-intervention.
Pre-intervention (<24 h of age) 24–48 h post-intervention 72–96 h post-intervention
Group 1 Group 2 Group 3 p-Valueb Group 1 Group 2 Group 3 p-Value Group 1 Group 2 Group 3 p-Value
n = 39a n = 37 n = 35 n = 17 n = 15 n = 0c n = 20 n = 20 n = 25
Iron (mol/L) 12.2 14.2 10.6 0.08 12.0 11.3 – 0.65 14.0 12.7 13.2 0.72
Male  11.5 13.4 11.4 0.55 11.3 10.5 0.49 14.0 12.0 12.5 0.55
Female  12.9 15.3 9.6 0.08 12.7 12.8 0.98 14.0 13.1 13.9 0.97
TSAT  (%) 22.8 27.5 23.1 0.37 22.5 22.2 – 0.89 29.4 28.1 27.4 0.88
Male  21.1 26.4 22.9 0.46 22.8 21.2 0.72 30.5 27.2 24.3 0.30
Female  25.3 28.9 23.4 0.71 22.0 24.1 0.79 28.2 28.9 30.9 0.93
Hepcidin  (ng/ml)d 74.5 72.9 56.9 0.52 40.9 49.8 – 0.41 91.0 91.7 66.5 0.32
Male  76.7 100.2 63.1 0.74 35.1 49.4 0.51 80.9 85.1 89.2 0.87
Female  72.0 54.0 51.6 0.33 49.7 50.3 0.86 101.3 98.8 48.4 0.004
IL-6  (pg/ml)d 22.0 22.6 21.6 0.71 21.4 21.7 – 0.12 6.3 7.5 7.1 0.90
Male  30.6 28.1 21.3 0.62 24.5 18.1 0.02 5.8 10.3 7.6 0.54
Female  15.8 17.4 22.0 0.44 16.7 26.1 0.39 6.8 5.3 6.6 0.94
Ferritin  (g/L) 333.6 324.2 330.9 0.99 308.7 337.3 – 0.43 259.1 256.3 283.5 0.75
Male  287.0 282.8 367.0 0.85 250.4 293.9 0.54 227.9 235.1 285.0 0.53
Female  393.6 371.5 240.6 0.27 396.2 380.7 0.92 304.3 268.2 281.6 0.86
Haemoglobin (g/dL) 17.9 17.2 17.8 0.47 18.8 19.5 – 0.45 18.5 17.4 17.7 0.65
Male  17.4 16.8 17.2 0.72 18.0 19.5 0.10 18.3 15.7 17.5 0.15
Female  18.4 17.7 18.5 0.70 20.0 19.4 0.60 18.6 19.5 17.9 0.68
a Number for each group is the maximum number of blood samples available. Not all parameters were available for all samples due to volume constraints.
w
1
r
a
i
b
m
w
d
I
a
d
i
o
l
i
i
b
n
p
i
n
A
a
n
t
L
c
G
m
C
[
[
[
[b One-way ANOVA.
c Infants in group 3 were only sampled at the 72–96 h sampling time-point.
d Geometric means.
Second, mean IL-6, hepcidin and ferritin levels in these neonates
ere high, with IL-6 initially 10–20 fold higher [15], hepcidin
.5–2 fold higher [16] and ferritin 5–10 fold higher [17] than
eported circulating levels in older children. Correspondingly TSAT
nd iron levels were at the lower end of the normal range, approx-
mately 50% lower than previously reported ranges from cord
lood [18]. This suggests that the inﬂammatory-iron axis, whether
ediated by hepcidin-dependent or independent pathways [19]
as already stimulated in all of our study participants, perhaps
ue to acute inﬂammation precipitated by the birth process [20].
f the axis is already maximally stimulated in these infants any
dditional impact of BCG or other vaccines would not have been
etectable. The non-speciﬁc effects of BCG are reportedly highest
n low birth-weight/premature infants. It may  be that stimulation
f the inﬂammatory-iron axis at birth is blunted in this popu-
ation and is enhanced by immunisations. Thus, impacts on the
ron-inﬂammatory axis cannot be ruled out as a potential biolog-
cal mechanism to explain the non-speciﬁc effects of BCG in such
abies.
To fully understand whether BCG and other routine immu-
isations have an impact on iron metabolism, similar studies in
remature neonates and older infants, from different geograph-
cal regions and with longer blood sampling time points, are
ecessary.
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